منابع مشابه
Ab wann kann man mit Kindern Informatik machen? / Eine Studie über informatische Fähigkeiten von Kindern
Durch Ausstattungsprogramme einzelner Länder unterstützt zieht der Computer inzwischen verstärkt auch in Grundschulen ein, z.B. in Form von Medieninseln. Auch wenn er dort vor allem im Fachunterricht verwendet werden soll, werden Erläuterungen beim Zugang zugleich eine Reihe von kerninformatischen Sachverhalten berühren. Im Gefolge der aktuellen Diskussion um die Ausbildung der Informatik (Gree...
متن کاملPhase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
This phase 2 trial was designed to evaluate ixazomib, an orally bioavailable proteasome inhibitor, in patients with myeloma who have limited prior exposure to bortezomib. Thirty-three patients with relapsed multiple myeloma were enrolled. Ixazomib was given at 5.5 mg weekly for 3 of 4 weeks. Dexamethasone was added for lack of a minor response (MR) by end of cycle 2 or lack of a partial respons...
متن کاملTIPSTER Phase III Goals
The primary goal of TIPSTER Phase III is to promote advancements in text processing technologies. To accomplish this goal, the TIPSTER Program will continue to encourage the cooperation of researchers and developers in government, industry and academia to achieve a balanced overall program. The Phase III framework is modeled on that of Phase II and will consist of four basic components: (1) Adv...
متن کاملTIPSTER Phase III Accomplishments
The overall purpose was to field a system for use within the operational elements of the Intelligence community and other Government agencies. Phase III Government participants included the Defense Advanced Research Projects Agency (DARPA), the Central Intelligence Agency (CIA), the National Security Agency (NSA), the National Institute of Standards and Technology (NIST), the Naval Research Lab...
متن کاملPopulation Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
Ixazomib is an oral proteasome inhibitor, approved in USA, Canada, Australia and Europe in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. We report a population pharmacokinetic model-based analysis for ixazomib that was pivotal in describing the clinical pharmacokinetics of ixazomib, to inform pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Im Focus Onkologie
سال: 2016
ISSN: 1435-7402,2192-5674
DOI: 10.1007/s15015-016-2853-y